JOEL LURIE: Open Payments
NPI 1497273841 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$691 in 17 payments from 13 companies in 2025. Trend: 2023 $706 · 2024 $630 · 2025 $691
Food & beverage: $691
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 2 | $145 |
| GlaxoSmithKline, LLC. | 1 | $122 |
| ABBVIE INC. | 1 | $120 |
| Janssen Biotech, Inc. | 1 | $45 |
| Lilly USA, LLC | 2 | $43 |
| TerSera Therapeutics LLC | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 1 | $33 |
| Amgen Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $26 |
Products named: VYVGART, NUCALA, SKYRIZI, TREMFYA, KISUNLA, Quzyttir, SAPHNELO, INJECTAFER.
Industry payments across TX — which companies pay providers there.
